GlassScriptPhysician profile
Corey R Segars
NPI 1366603565
$3,248.77
in general payments reported to CMS, 2019-2025
13 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $568 · 2022: $1,147 · 2023: $799 · 2024: $475 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.81 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $621.31 | 2021-2025 | Ingrezza |
| Indivior INC. | $360.63 | 2021-2023 | Perseris |
| Janssen Pharmaceuticals, INC | $338.58 | 2021-2025 | Invega Sustenna |
| Alkermes, INC. | $319.82 | 2021-2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $197.98 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.34 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $164.24 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $159.64 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $126.33 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $48.46 | 2022-2024 | Abilify Maintena |
| Eisai INC. | $22.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.91 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Segars listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.